Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

  • STATUS
    Not Recruiting
  • End date
    Dec 28, 2025
  • participants needed
    12
  • sponsor
    Mayo Clinic
Send
Updated on 19 February 2024
See if I qualify
dupilumab
chronic pruritus

Summary

To investigate the potential efficacy of dupilumab in the treatment of moderate to severe chronic hepatic pruritus.

Description

This is a 22-week (2 week screening, 18-week treatment period followed by a 2 week followup), phase II, open label, exploratory study to investigate the potential efficacy of FDA approved dupilumab in the treatment of adults with moderate to severe chronic hepatic pruritus. Subjects will be screened at outpatient clinic visit appointments and interested qualified subjects will be consented and offered participation in this trial. Once consent has been obtained, baseline values will be established and subjects will begin treatment and follow-up for the next 20 weeks. A final visit will be needed for evaluation and questionnaire completion.

Details
Condition Pruritus, Dermatosis
Age 18years - 100years
Treatment Dupilumab 300Mg Solution for Injection
Clinical Study IdentifierNCT04256759
SponsorMayo Clinic
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

b'Male and/or female subjects 18 years or older with chronic pruritus of moderate to'
b'evere severity in the setting of intrahepatic or extrahepatic cholestatic liver'
b'disease. Chronic is defined as greater than 6 weeks of symptom duration. Pruritus'
b'everity is based on the peak pruritus numerical rating score of \\u2265 4 (moderate'
b'everity).'
b'Documentation of a personally signed and dated informed consent indicating that the'
b'ubject has been informed of all pertinent aspects of the trial.'
b'Willingness and ability to comply with scheduled clinic visits, physical exams,'
b'laboratory tests, questionnaires, and other trial procedures.'

Exclusion Criteria

b'Male and/or female subjects under 18 years of age.'
b'Pruritus due to a primary inflammatory skin dermatosis or other forms of psychogenic'
b'pruritus utilizing skin biopsies as needed.'
b'Pregnant females'
b'History of intrahepatic cholestasis of pregnancy'
b'Any form of chronic hepatic pruritus associated with underlying malignancy'
b'Liver transplant recipients'
b'Allergy to dupilumab or its ingredients'
b'Inability to provide informed consent'
b'Concomitant use of selective opioid antagonists'
b'Subjects with severe asthma (requiring high-dose inhaled or systemic corticosteroids)'
b'will be excluded from the study.'
b'Patients with known helminth infections'
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

dupilumab
chronic pruritus

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.